ReviewAmerican journal of respiratory and critical care medicine2025
Is Disease Stability an Attainable Chronic Obstructive Pulmonary Disease Treatment Goal?
Review in American journal of respiratory and critical care medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Defining disease stability in chronic obstructive pulmonary disease: evidence from phase 3 clinical trials.American journal of respiratory and critical care medicine · 2026Trial
- Response to letter regarding "clinical impact of disease stability on exacerbation and mortality in chronic obstructive pulmonary disease".Annals of medicine · 2026Article
- Clinical impact of disease stability on exacerbation and mortality in COPD: a retrospective cohort study.Annals of medicine · 2026Article
- Regarding: clinical impact of disease stability on exacerbation and mortality in COPD: a retrospective cohort study.Annals of medicine · 2026Article
- Airway mucus plugs in asthma and chronic obstructive pulmonary disease: pathobiology, imaging, and implications for clinical trials.American journal of respiratory and critical care medicine · 2026Review
- Adjuvanted RSVPreF3 vaccine impact over three respiratory syncytial virus seasons in older adults with comorbidities.ERJ open research · 2026Article
- A Hybrid Care Intervention for High-Risk Patients With Chronic Obstructive Respiratory Disorders: Mixed Methods Co-Design Study.Journal of medical Internet research · 2026Article
- COPD Stability and Asthma Remission: Different Words for the Same Therapeutic Ambition?Biomedicines · 2026Review
- Clinically relevant change in airway wall thickness to identify disease activity in COPD and smokers at risk.The European respiratory journal · 2026Article
- Impact of Single-Inhaler Triple Therapy FF/UMEC/VI on Disease Stability in COPD: A Real-World 12-Month Analysis.Pulmonary therapy · 2026Article
- Association Between Phase Angle, Muscle Mass Distribution, and Quality of Life in Patients with Chronic Obstructive Pulmonary Disease.Journal of clinical medicine · 2026Article
- Beyond Eosinophil Depletion: IL-5 as a Context-Dependent Regulator of Airway Immune Networks.International journal of molecular sciences · 2026Review
- Transitions to and reversion from a persistent frequent-exacerbator state in COPD.ERJ open research · 2026Article
- Development and validation of a risk stratification tool for predicting COPD exacerbations in patients without prior exacerbation history.BMJ open respiratory research · 2026Article
- Exploring COPD Participants' Experiences in a Comprehensive Telewellness Program within a Mixed-Disability Cohort: A Qualitative Study.International journal of chronic obstructive pulmonary disease · 2026Article
- Real-Life Effectiveness of Aclidinium/Formoterol on COPD Control: The REDACT Observational Study.International journal of chronic obstructive pulmonary disease · 2026Observational
- Real-World Effectiveness and Safety of Extrafine Triple Therapy in COPD Patients with Comorbid and Cardiovascular Conditions.International journal of chronic obstructive pulmonary disease · 2026Article
- Biological treatments for asthma and chronic obstructive pulmonary disease.BMJ medicine · 2026Review
- Inhalable extracellular vesicles as cell-free therapeutics for chronic respiratory disease.Frontiers in bioengineering and biotechnology · 2026Review
- Convergent death programs in chronic obstructive pulmonary disease: how pyroptotic and ferroptotic crosstalk reshapes therapeutic paradigms.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic obstructive pulmonary disease (COPD) is a heterogeneous lung condition characterized by progressive airflow obstruction. Despite advancements in diagnosis and treatment, the disease burden remains high; although clinical trials have shown improvements in outcomes such as exacerbations, quality of life, and lung function, improvement may not be attainable for many patients. For patients who do experience improvement, it is challenging to set management goals given the progressive nature of COPD. We therefore propose disease stability as an appropriate and attainable treatment goal. Other disease areas have developed definitions of no disease activity or remission, which provide relevant information for defining and achieving stability for patients with COPD. Disease stability builds on related concepts already defined in COPD, such as clinical control and clinically important deterioration. Current components that could form part of a disease stability definition include exacerbations, health status (including quality of life and symptoms), and lung function. Considerations should be given to intervals over which stability is defined and assessed, appropriate thresholds, and defining a composite. Ensuring a holistic approach, objective measurements, and harmonious, clear communication between patients and physicians can further support establishing disease stability. Here we propose a preliminary definition of disease stability, informed by existing research in COPD. Further research will be needed to validate the framework for use in clinical and research settings. Exploring disease stability as a goal, however, is an opportunity to develop and validate an attainable treatment target to advance the standard of care for patients with COPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.